Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
Nelli F, Giannarelli D, Fabbri A, Silvestri MA, Berrios JRG, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Onorato A, Panichi V, Topini G, Pessina G, Natoni F, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Ann Oncol. 2022 Jul;33(7):740-742. doi: 10.1016/j.annonc.2022.04.002. Epub 2022 Apr 9. Ann Oncol. 2022. PMID: 35413398 Free PMC article. No abstract available.
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Giron Berrios JR, Virtuoso A, Marrucci E, Signorelli C, Chilelli MG, Primi F, Schirripa M, Mazzotta M, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Ann Oncol. 2022 Jan;33(1):107-108. doi: 10.1016/j.annonc.2021.09.009. Epub 2021 Sep 20. Ann Oncol. 2022. PMID: 34555502 Free PMC article. No abstract available.
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Pessina G, Giron Berrios JR, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Panichi V, Cercola P, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Ann Oncol. 2022 Mar;33(3):352-354. doi: 10.1016/j.annonc.2021.12.001. Epub 2021 Dec 10. Ann Oncol. 2022. PMID: 34896598 Free PMC article. No abstract available.
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM, Nelli F, Fabbri A, Onorato A, Giannarelli D, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Panichi V, Pessina G, Signorelli C, Chilelli MG, Primi F, Natoni F, Fazio S, Silvestri MA. Ruggeri EM, et al. Among authors: silvestri ma. ESMO Open. 2022 Feb;7(1):100350. doi: 10.1016/j.esmoop.2021.100350. Epub 2021 Nov 27. ESMO Open. 2022. PMID: 34942438 Free PMC article.
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study.
Nelli F, Fabbri A, Panichi V, Giannarelli D, Topini G, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Int Immunopharmacol. 2022 Jul;108:108774. doi: 10.1016/j.intimp.2022.108774. Epub 2022 Apr 14. Int Immunopharmacol. 2022. PMID: 35461110 Free PMC article.
Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy.
Nelli F, Panichi V, Fabbri A, Natoni F, Giannarelli D, Topini G, Virtuoso A, Giron Berrios JR, Marrucci E, Pessina G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Cancer Invest. 2022 Sep;40(8):710-721. doi: 10.1080/07357907.2022.2092635. Epub 2022 Jun 26. Cancer Invest. 2022. PMID: 35736808
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients.
Ruggeri EM, Nelli F, Giannarelli D, Fabbri A, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Fiore C, Panichi V, Topini G, Silvestri MA. Ruggeri EM, et al. Among authors: silvestri ma. Sci Rep. 2022 Dec 19;12(1):21908. doi: 10.1038/s41598-022-25558-8. Sci Rep. 2022. PMID: 36535985 Free PMC article.
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Pessina G, Natoni F, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Curr Oncol. 2023 May 17;30(5):5103-5115. doi: 10.3390/curroncol30050386. Curr Oncol. 2023. PMID: 37232844 Free PMC article.
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10. Cancer Immunol Immunother. 2023. PMID: 37428196 Free PMC article.
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study.
Nelli F, Signorelli C, Fabbri A, Giannarelli D, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: silvestri ma. Cancers (Basel). 2023 Jul 14;15(14):3625. doi: 10.3390/cancers15143625. Cancers (Basel). 2023. PMID: 37509286 Free PMC article.
21 results